These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
35. Low plasma reduced haloperidol/haloperidol ratios in Chinese patients. Chang WH; Chen TY; Lee CF; Hu WH; Yeh EK Biol Psychiatry; 1987 Nov; 22(11):1406-8. PubMed ID: 3663790 [No Abstract] [Full Text] [Related]
36. Interindividual variation in bromperidol metabolism and relationship to therapeutic effects. Someya T; Muratake T; Hirokane G; Shibasaki M; Shimoda K; Takahashi S J Clin Psychopharmacol; 2000 Apr; 20(2):175-80. PubMed ID: 10770455 [TBL] [Abstract][Full Text] [Related]
37. Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre study. Wistedt B; Koskinen T; Thelander S; Nerdrum T; Pedersen V; Mølbjerg C Acta Psychiatr Scand; 1991 Jul; 84(1):14-21. PubMed ID: 1681680 [TBL] [Abstract][Full Text] [Related]
38. Pharmacoclinical correlations in schizophrenic patients treated with haloperidol decanoate: clinical evaluations, concentrations of plasma and red blood cell haloperidol and its reduced metabolite, and plasma homovanillic acid. Aymard N; Viala A; Stein I; Caroli F Prog Neuropsychopharmacol Biol Psychiatry; 1995 Nov; 19(7):1119-35. PubMed ID: 8787036 [TBL] [Abstract][Full Text] [Related]
39. Clinical pharmacokinetics of the depot antipsychotics. Jann MW; Ereshefsky L; Saklad SR Clin Pharmacokinet; 1985; 10(4):315-33. PubMed ID: 2864156 [TBL] [Abstract][Full Text] [Related]
40. Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment. Ulrich S; Neuhof S; Braun V; Danos P; Pester U; Hoy L J Clin Psychopharmacol; 2000 Apr; 20(2):210-9. PubMed ID: 10770460 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]